Enliven Therapeutics is a leading biopharmaceutical company that is dedicated to discovering and developing small molecule kinase inhibitors for the treatment of cancer. With a precision oncology approach, they aim to improve the survival and overall well-being of cancer patients. By combining clinically validated biological targets and cutting-edge chemistry, Enliven Therapeutics strives to design best-in-class and first-in-class therapies.

Their team consists of world-renowned chemists and precision oncology experts who have been involved in the discovery, development, and commercialization of multiple small molecule kinase inhibitor programs. They have a track record of success in building and leading research, development, and commercial operations at top pharmaceutical companies. Enliven Therapeutics' product pipeline includes programs targeting BCR-ABL and HER2, among others.

They are dedicated to developing drugs with a high probability of clinical success and aim to revolutionize cancer treatment. Discover more about their innovative approach and the exceptional team behind their groundbreaking work on their website